A Slowly Developed Severe Cutaneous Adverse Reaction to Idelalisib

Intracellular signal mediator phosphatidylinositol-3-kinase (PIK3K) –δ, an isoform of PIK3K, is expressed in hematopoietic cells especially in lymphoid lineage 1. Idelalisib is a novel PIK3K-δ targeted kinase inhibitor which is approved for relapsed follicular B-cell non-Hodgkin lymphoma as a monotherapy and in combination with rituximab, an anti-CD20 antibody, for relapsed chronic lymphocytic leukemia (CLL) 2. Only one case describing the clinical features of severe cutaneous adverse reaction (SCAR) of idelalisib in detail has been previously published 3. Here we expand the clinical picture of SCAR caused by idelalisib with its histological profile.

This article is protected by copyright. All rights reserved.

http://ift.tt/2AYxMNJ